On Friday, CFRA, a financial research firm, increased its price target on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) to DKK950 from the previous DKK810, while keeping a Hold rating on the stock. The adjustment reflects a price-to-earnings (P/E) ratio of 42 times for the year 2024, which is higher than the company's three-year average P/E of 32 times. The analyst believes this premium is justified by the anticipated higher growth for the pharmaceutical company.
Novo Nordisk recently confirmed its strategic goals for 2025 during its Capital Market Day. These aspirations include generating over DKK25 billion in sales from its Obesity division by 2025. The company has a robust pipeline of experimental drugs for obesity treatment, such as CagriSema and amycretin. These drugs are expected to bolster future growth in addition to the current approved obesity medications, Wegovy and Saxenda.
Investors have responded positively to the promising data from the oral amycretin phase 1 trial. However, results for the subcutaneous version of amycretin from the phase 1 trial will not be available until 2025.
Despite the increased competition in the obesity treatment market, notably from the recent introduction of Eli Lilly (NYSE:LLY)'s Zepbound, CFRA anticipates that Novo Nordisk will still achieve double-digit growth in 2024, aligning with the company's guidance. The analyst's estimates for the company remain unchanged despite the new price target.
InvestingPro Insights
Novo Nordisk (NYSE: NVO) has been demonstrating a strong financial performance with several noteworthy metrics to consider for investors. According to InvestingPro data, the company boasts a substantial market capitalization of $596.82 billion USD, indicating its significant presence in the pharmaceuticals industry. Moreover, Novo Nordisk has shown a remarkable revenue growth of 31.26% over the last twelve months as of Q4 2023, outpacing many competitors and highlighting its robust sales capabilities.
InvestingPro Tips suggest that Novo Nordisk has been a reliable dividend payer, having raised its dividend for 6 consecutive years and maintaining dividend payments for 35 consecutive years, which could be a reassuring sign for income-focused investors. Additionally, with a P/E ratio adjusted for the last twelve months of Q4 2023 at 47.95, the company is trading at a low P/E ratio relative to near-term earnings growth, potentially offering an attractive valuation for growth investors.
Investors may also be encouraged by the company's recent price performance, with a 1-month price total return of 14.81% and a 3-month price total return of 40.65%, reflecting significant recent gains. For those seeking further analysis, InvestingPro offers additional insights and metrics, with 22 more InvestingPro Tips available for Novo Nordisk. These include assessments of debt levels, earnings multiples, and price volatility, providing a comprehensive view of the company's financial health and market performance.
For readers interested in a deeper dive into Novo Nordisk's investment potential, they can explore these tips and more by visiting InvestingPro. Use the exclusive coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing your investment research with valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.